Technology | January 19, 2015

FDA Grants HDE For Pacemaker That Regulates Hypertension

Device used to control drug-resistant hypertension via implantable pulse generator

CVRx, Barostim neo Legacy System, pacemaker, hypertension, FDA, HDE

January 19, 2015 — The U.S. Food and Drug Administration (FDA) has granted a humanitarian device exemption for the CVRx Inc. Barostim neo Legacy System.

The Barostim neo System is a programmable, minimally invasive device that consists of an implantable pulse generator (IPG), a 2-mm electrode and an external programmer. Barostim therapy is designed to trigger the natural blood pressure regulation system by electrically activating the carotid baroreceptors. The device is commercially available in Europe and the United States. The therapy is included in the joint European Society of Hypertension and European Society of Cardiology guidelines for the treatment of resistant hypertension published in June 2013.

The system is completed by connecting the IPG to electrical stimulation lead electrodes placed on the carotid sinus nerves on each side of the neck. The device provides controlled delivery of high-frequency, small electrical stimulation pulses to the carotid sinus. This has been shown to provide probable benefit to patients with resistant hypertension who have already been determined to respond to this treatment by lowering their systolic and diastolic blood pressure.

The Barostim neo Legacy System may be used in patients with resistant hypertension who were previously implanted in clinical trials with the Rheos Carotid Sinus Leads Models 1010R, 1010L, 1014L, and 1014R which have now been discontinued and are no longer available. Specifically, the approved IPG will replace an existing IPG in a patient whose battery is depleted and needs to be replaced and/or electrode lead repair procedures are necessary.

Use of the Barostim neo Legacy System may help patients who achieved a significant lowering of their blood pressure during their participation in the clinical trial to maintain those results. Clinical trial results showed that in these patients the systolic and diastolic blood pressure was lowered by an average of 33.6 mmHg and 17.5 mmHg, respectively.

For more information: www.fda.gov

Related Content

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Text Messaging Could Help Tackle High Blood Pressure in At-Risk Patients

Image courtesy of Michigan Medicine

News | Hypertension| September 06, 2017
A new National Institutes of Health-funded hypertension trial will examine the possibility of using an emergency...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
SPYRAL HTN-OFF MED Study Results Show Efficacy, Safety of Renal Denervation
News | Renal Denervation| August 31, 2017
Medtronic plc announced its intent to move forward with a new renal denervation pivotal trial following positive first...
MobiusHD Device Shows Promise in Treatment of Resistant Hypertension
News | Hypertension| August 30, 2017
Vascular Dynamics Inc. announced interim results of the company’s first-in-human trial of its MobiusHD implant...
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Overlay Init